A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco

A Retrospective Observational Non-Interventional Study (NIS) to Assess Patient Characteristics Among COVID-19 Patients Receiving Treatment With Nirmatrelvir/Ritonavir (PAXLOVIDTM) in Morocco.

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05997485

Enrollment

Registered

2023-08-18

Start date

2024-03-30

Completion date

2024-06-30

Last updated

2024-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Drug Treatment

Keywords

Treatment, Covid Patient, Paxlovid, Morocco

Brief summary

The purpose of this study is to collect information on the: * general information of a group of people such as their age, sex, and other facts. * clinical information of the patients such as any other illness before having COVID 19. In adult patients with COVID-19 who have been prescribed nirmatrelvir and ritonavir treatment. This study will be conducted in Morocco. The study will capture information of the adult COVID-19 outpatients and inpatients who have been prescribed nirmatrelvir, ritonavir treatment. The inpatients will be admitted in the hospital for other reasons than COVID-19. This study will have about 150 patients. The study will involve collection of patient information from medical records. The information collected can be either from papers or from computers. The study will include patient information of those who: * are confirmed to have COVID-19 infection during the study period from 01 June 2022 to 30 June 2023. * are 18 years of age or older. * are prescribed Nirmatrelvir and ritonavir. This study will help to inform decision-making on use of Paxlovid at the national level.

Interventions

DRUGNirmatrelvir/Ritonavir

Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Confirmed COVID-19 infection during the study period from 01 June 2022 to 30 June 2023 * Nirmatrelvir, ritonavir written prescription

Exclusion criteria

* There are no

Design outcomes

Primary

Measure	Time frame
Demographical Characteristics of Participants	Approximately 01 June 2022 through 30 June 2023
Clinical Characteristics of Participants	Approximately 01 June 2022 through 30 June 2023
Number of Participants with Pre-existing Comorbidities	Approximately 01 June 2022 through 30 June 2023

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026